Skinfix

Amy Gordinier grew up watching skincare get manufactured. Her father ran manufacturing for Estée Lauder, which gave her an early, factory-floor appreciation for how formulas actually get made, and she went on to spend roughly two decades in the business, including a stretch at Jo Malone learning the craft from a fragrance disruptor. So when she relocated to Nova Scotia to raise her children and stumbled onto a woman whose family had been quietly making a Victorian healing balm for generations, she recognized something most people would have missed: four pharmaceutical-grade actives sitting at their genuinely active levels, plus a shoebox of handwritten testimonials documenting decades of real results. She mortgaged her home to buy the name, the formula, and the brand DNA outright. The pivotal move came next. A Canadian dermatologist she approached refused to engage without data, so Gordinier commissioned clinical studies, first a small one, then a thirty-patient trial pitting the balm directly against hydrocortisone cream, where it held its own and pulled ahead on barrier repair over time. That insistence on validating a heritage folk remedy with controlled trials became the engine of everything: more than thirty studies followed across five years of dermatology collaboration, expanding the line from eczema into rosacea and keratosis pilaris, all organized around the single obsession of barrier health. The retail story tracked the credibility story, with the brand migrating from mass-market drugstore shelves to prestige placement and explosive growth once "clean" and "clinical" stopped being treated as opposites. A private-equity stake later funded the acceleration while keeping the founder in charge. The takeaway is unusual for the clean-beauty aisle: this is a brand whose claims were stress-tested against an actual drug, not just asserted on a label.

Sources:[1][2][3][4]